| Methods |
4‐to 5‐week placebo run‐in; inclusion criteria= mean sitting DBP 95‐110 mm Hg on days 22, 29 and, if necessary, day 36 (± 3 days) of run‐in; 8‐week double‐blind treatment |
| Participants |
Irbesartan 75 mg once daily: n=55(37 males,18 females); mean age=56.7(10.4) years; baseline sitting SBP=157.0(13.4) mm Hg, DBP=101.4(5.2) mm Hg;
Irbesartan 150 mg once daily: n=53(32 males,21 females); mean age=54.6(11.7) years; baseline sitting SBP=158.9(13.8) mm Hg, DBP=101.0(5.1) mm Hg;
Irbesartan 75 mg twice daily: n=57(36 males,21 females); mean age=54.1(10.6) years; baseline sitting SBP=156.0(12.8) mm Hg, DBP=106.7(4.5) mm Hg;
Placebo: n=50(36 males,14 females); mean age=53.3(11.3) years; baseline sitting SBP=158.3(13.4) mm Hg, DBP=101.5(5.0) mm Hg |
| Interventions |
Irbesartan 75 mg once daily;
Irbesartan 150 mg once daily;
Irbesartan 75 mg twice daily;
Placebo;
once daily dosing: morning dose taken between 7 AM and 10 AM;
twice daily dosing: morning dose taken between 7 AM and 10 AM and evening dose approximately 12 h later |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported, baseline SD reported; calculated SD from N and SE; BP data from Table 2, p. 1515; Jadad score=4; funding source= Bristol‐Myers Squibb and Sanofi |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
